Previous 10 | Next 10 |
2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...
2023-08-13 14:00:00 ET A recently introduced piece of legislation in the House that would allow drug price negotiations and inflation rebates on behalf of those with private insurance could potentially harm pharma companies' bottom line. The Lowering Drug Costs for American Families Act...
2023-08-13 12:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-08-10 13:25:23 ET Baird has lowered its rating on Decibel Therapeutics ( NASDAQ: DBTX ) to neutral following news that Regeneron ( REGN ) plans to buy the biotech for around $109M in cash, plus contingency value rights, or CVRs. The investment bank said it believes the ...
88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the end of two years 78% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals throughout the two-year study period 71% met the extension criteria for even longer dosing inte...
2023-08-10 05:21:00 ET If you look at the S&P 500 , which is up more than 18% this year, or the Nasdaq Composite , which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech stocks, it appears they are still caught up in a down...
2023-08-09 08:06:59 ET Regeneron Pharmaceuticals ( NASDAQ: REGN ) has agreed to acquire Decibel Therapeutics ( DBTX ), a micro-cap biotech focused on developing gene therapies for hearing disorders, for $4.00 per share in cash plus a contingent value right, the companies announc...
Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel’s lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related ...
2023-08-08 12:15:25 ET Stifel, Guggenheim, Jefferies and Wedbush have initiated coverage of dermatology drug developer Apogee Therapeutics ( NASDAQ: APGE ) with buy ratings and price targets ranging from $29 to $40. Stifel said in its note that Apogee's lead drug program APG777 ...
2023-08-06 09:00:00 ET Technological progress sometimes renders products or entire industries completely obsolete. That's true even within the healthcare sector, which as a whole is unlikely to fall out of style anytime soon. Even so, individual healthcare companies must constantly innovate...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...